AGPAT5 Knockout Jurkat Polyclonal Cells represent a heterogeneous population of Jurkat cells with CRISPR/Cas9-mediated disruption of the AGPAT5 gene. This polyclonal knockout product provides a robust loss-of-function model for interrogating AGPAT5-dependent processes without clonal selection artifacts. The cell population retains the fundamental characteristics of the parental Jurkat line while harboring a diverse array of edits at the AGPAT5 locus, enabling functional studies in a physiologically relevant T lymphocyte background.
The Jurkat cell line is an immortalized human T lymphocyte line derived from the peripheral blood of a 14-year-old male with acute T cell leukemia. Widely used to investigate T cell receptor signaling, apoptosis, and leukemia, Jurkat cells provide a well-characterized platform for gene knockout studies. Their active phospholipid turnover and signaling make them a relevant cellular environment for examining enzymes such as AGPAT5 that regulate glycerolipid biosynthesis.
AGPAT5 (1-acylglycerol-3-phosphate O-acyltransferase 5) is an ER-resident enzyme that catalyzes the conversion of lysophosphatidic acid (LPA) to phosphatidic acid (PA), a critical step in de novo phospholipid and triacylglycerol synthesis. Its activity is regulated upstream by SREBP transcription factors and LPA availability. PA generated by AGPAT5 serves as a precursor for diacylglycerol (DAG) and downstream phospholipids, and also functions as a signaling lipid modulating membrane dynamics and protein recruitment. AGPAT5 interacts with other glycerolipid synthesis enzymes such as GPAT and lipins, integrating into a network that includes multiple AGPAT isoforms. Disruption of AGPAT5 perturbs the LPA-to-PA equilibrium, potentially altering lipid-mediated signal transduction and cellular membrane composition.
In Jurkat T cells, phospholipid metabolism is tightly coupled to signaling events including T cell receptor activation, proliferation, and apoptosis. AGPAT5 loss in this leukemia-derived model likely alters membrane composition and bioactive lipid mediator availability. Phosphatidic acid participates in mTOR signaling and vesicle trafficking; thus, AGPAT5 knockout may impair T cell responses and leukemic cell growth. This model serves as a valuable tool to investigate how perturbed phospholipid synthesis drives oncogenic phenotypes and reveals cancer lipid metabolism vulnerabilities.
This polyclonal knockout product supports a range of experimental applications, including investigation of AGPAT5 function in T cell lipid metabolism, elucidation of phospholipid-mediated signaling in apoptosis and proliferation, and cancer cell biology research. Representative assays include western blotting, RT-qPCR, lipidomic profiling to quantify LPA, PA, and related species, flow cytometry for apoptosis and cell cycle analysis, and enzyme activity measurements. For further information or technical support, please contact Ascent Research.
